Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2000-11-30

Study Completion Date

2009-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

S0014 Combination Chemotherapy Plus Rituximab and Radiation Therapy in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NCT00005089

Lymphoma

COMPLETED PHASE2

Rituximab in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease

NCT00003849

Lymphoma

COMPLETED PHASE2

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

NCT00022685

Lymphoma

UNKNOWN PHASE3

Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma (Low-Grade)

NCT00044902

Non-Hodgkin's Lymphoma

COMPLETED PHASE2

Epratuzumab and Rituximab in Treating Patients With Previously Untreated Follicular Non-Hodgkin Lymphoma

NCT00553501

Lymphoma

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphoma, Non-Hodgkin Lymphomas: Non-Hodgkin Lymphomas: Non-Hodgkin Cutaneous Lymphoma Lymphomas: Non-Hodgkin Diffuse Large B-Cell Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell Lymphomas: Non-Hodgkin Mantle Cell Lymphomas: Non-Hodgkin Marginal Zone Lymphomas: Non-Hodgkin Peripheral T-Cell Lymphomas: Non-Hodgkin Waldenstr Macroglobulinemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Rituximab

Intervention Type DRUG

Epratuzumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stanford University School of Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wen-Kai Weng

Role: PRINCIPAL_INVESTIGATOR

Stanford University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Stanford University School of Medicine

Stanford, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States